Anne Paulien Drenth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anne Paulien Drenth has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Bjørn Siteur
Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands
36 shared publications - Catrin Lutz
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
36 shared publications - Daniel Zingg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
36 shared publications - Eline van der Burg
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
36 shared publications - Ellen Wientjens
Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
36 shared publications - Jinhyuk Bhin
Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea
36 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-CC2-Pro construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-CC2-Pro construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S8 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tnip2 construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S8 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tnip2 construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
HALO-FGFR3 expression in NMuMG cells and FACS gating strategy used for the SPIDA assay
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
HALO-FGFR3 expression in NMuMG cells and FACS gating strategy used for the SPIDA assay
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
List of metastatic solid tumor samples harboring structural rearrangements affecting FGFR3 identified in the HMF cohort
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
List of metastatic solid tumor samples harboring structural rearrangements affecting FGFR3 identified in the HMF cohort
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Evaluation of tumor growth, drug exposure, and adaptive resistance emergence following fexagratinib treatment in Fgfr3ΔE18-Tacc3-driven mouse mammary tumors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Evaluation of tumor growth, drug exposure, and adaptive resistance emergence following fexagratinib treatment in Fgfr3ΔE18-Tacc3-driven mouse mammary tumors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S5 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-L772A/L773A construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S5 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-L772A/L773A construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Overview of FGFR3-truncating mutations in the FMI cohort and junction read ratios in HMF RNA-seq profiles
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Overview of FGFR3-truncating mutations in the FMI cohort and junction read ratios in HMF RNA-seq profiles
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S4 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-S764A construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S4 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-S764A construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3 construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3 construct
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-CC1-Pro construct
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S2 from C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
Detailed DNA and amino acid sequence of the Fgfr3ΔE18-Tacc3-CC1-Pro construct